Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Payables (2016 - 2026)

Dexcom has reported Payables over the past 17 years, most recently at $2.1 billion for Q1 2026.

  • Quarterly Payables fell 28.38% to $2.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Mar 2026, down 28.38% year-over-year, with the annual reading at $1.9 billion for FY2025, 30.31% down from the prior year.
  • Payables was $2.1 billion for Q1 2026 at Dexcom, up from $1.9 billion in the prior quarter.
  • Over five years, Payables peaked at $3.1 billion in Q2 2025 and troughed at $603.1 million in Q1 2022.
  • The 5-year median for Payables is $1.7 billion (2022), against an average of $1.8 billion.
  • Year-over-year, Payables skyrocketed 192.22% in 2022 and then crashed 30.31% in 2025.
  • A 5-year view of Payables shows it stood at $1.7 billion in 2022, then dropped by 19.64% to $1.3 billion in 2023, then skyrocketed by 107.32% to $2.8 billion in 2024, then crashed by 30.31% to $1.9 billion in 2025, then rose by 6.68% to $2.1 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Payables are $2.1 billion (Q1 2026), $1.9 billion (Q4 2025), and $3.1 billion (Q3 2025).